+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

  • ID: 4969149
  • Report
  • December 2019
  • Region: Global
  • 63 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

Summary

Human immunodeficiency virus (HIV) is a chronic disease that can be transmitted through blood, semen, and other bodily fluids by means such as sexual contact, pregnancy and breastfeeding, the sharing of injection drug equipment, and blood transfusions.

As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host. The loss of these cells leads to the progressive deterioration of the immune system, eventually resulting in the development of acquired immunodeficiency syndrome (AIDS), which is associated with multiple opportunistic infections.

Without treatment, HIV can progress to AIDS and may be fatal within a number of years. However, when appropriately managed with antiretroviral therapy (ART), HIV patients can achieve a near-normal life-expectancy.

Despite this, there is a continuing need to develop innovative new therapies for HIV, particularly among highly treated patients in whom HIV has developed resistance to one or more drugs.

Scope
  • The HIV pipeline is large, with more than 400 programs in active development. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
  • Approximately 50 first-in-class targets have been identified within the HIV pipeline. Among these, what is the distribution of host versus viral targets? Which of the host targets are considered to be most promising?
  • Across the HIV landscape, there are more than 250 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?
Reasons to buy
  • Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for HIV.
  • Analyze the HIV pipeline, and stratify pipeline assets by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class molecular targets. Using a proprietary matrix assessment, host first-in-class molecular targets for HIV have been assessed and ranked according to clinical potential, and the most promising of these targets are reviewed in greater detail. Key features of viral first-in-class targets are also outlined.
  • Analyze company strategies in prior deals through case studies of key deals for HIV first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 HIV: Executive Summary
2.1 Current Market Landscape Needs Further Novel Therapies
2.2 High Level of Pipeline Innovation Aims to Address Drug Resistance and Pill Burden
2.3 First-in-Class Therapies Target Latent HIV Reservoirs and Drug Resistance, with Potential for Prevention and Even Cure of HIV

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Sustained Innovation in HIV
4.4 Epidemiology for HIV
4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs Between HIV Market and Pipeline by Therapeutic Target Family
5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline

6 First-in-Class Molecular Target Evaluation
6.1 Overview
6.2 Pipeline Programs Targeting Interleukin 2 Receptor Subunit Beta IL2RB and Interleukin 2 Receptor Subunit Gamma
6.3 Pipeline Programs Targeting Toll-Like Receptor 3
6.4 Pipeline Programs Targeting Protein Kinase C Epsilon Type and Protein Kinase C Theta Type
6.5 Pipeline Programs Targeting CD209 Antigen
6.6 Pipeline Programs Targeting Cyclin-Dependent Kinase 9
6.7 Pipeline Programs Targeting Fc Fragment of IgG Low-Affinity III Receptor
6.8 Pipeline Programs Targeting 2’-5’-Oligoadenylate Synthetase 1
6.9 Pipeline Programs Targeting Serine/Arginine Rich Splicing Factor 10

7 Key Players and Deals
7.1 Overview
7.1.1 Gilead Sciences Entered a Co-development Deal with Aelix Therapeutics
7.1.2 GeoVax Labs Entered into a Co-development Deal with American Gene Technologies
7.1.3 BryoLogyx Entered into a Licensing Agreement with Stanford University

8 Appendix

List of Tables
Table 1: WHO Clinical Staging of HIV/AIDS for Adults and Adolescents with Confirmed HIV Infection, 2016
Table 2: HIV Total Prevalent Cases (N), 2015-2025

List of Figures
Figure 1: HIV, Global Market by Molecular Target and Molecule Type, 2019
Figure 2: HIV, Global, Pipeline by Stage of Development and Molecule Type, 2019
Figure 3: HIV, Global, Pipeline by Molecular Target and Stage of Development, 2019
Figure 4: HIV Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
Figure 5: HIV, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
Figure 6: HIV, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
Figure 7: HIV, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll